Printed From BioPortfolio.com

Ambrx Enters $143.5 Million China Deal for Liver Cancer Treatment

01:51 EST 22 Dec 2017 | ChinaBio Today

Ambrx announced a $143.5 million agreement to in-license China rights for a liver cancer treatment with an anti-angiogenesis mechanism, developed by Tracon Pharma of San Diego. Two years ago, Ambrx, a San Diego-Shanghai antibody-conjugate biotech company, was acquired by Fosun Pharma (SHA: 600196; HK: 02196) and WuXi PharmaTech plus two China equity investors. The new agreement gives Ambrx rights to Tracon's proprietary endoglin antibody, TRC105 (carotuximab), in greater China. More details....

Stock Symbol: (NSDQ: TCON)

Share this with colleagues:

Original Article: Ambrx Enters $143.5 Million China Deal for Liver Cancer Treatment

More From BioPortfolio on "Ambrx Enters $143.5 Million China Deal for Liver Cancer Treatment"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches